Physician profile
Jayesh G Kanuga
NPI 1689607871
$17,315.77
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $3,629 · 2021: $1,469 · 2022: $62.70.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $10,932.03 | 2019-2021 | |
| Genzyme Corporation | $4,460.72 | 2019-2020 | |
| Alk-Abello, INC | $1,322.01 | 2019 | |
| Glaxosmithkline, LLC. | $144.53 | 2019-2021 | |
| Boston Scientific Corporation | $120.96 | 2019 | |
| Pfizer INC. | $73.29 | 2019-2020 | |
| Optinose US, INC. | $62.70 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.60 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $38.16 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $37.28 | 2019 | |
| Genentech USA, INC. | $36.35 | 2019-2020 | |
| Horizon Therapeutics Plc | $14.86 | 2019 | |
| Pharming Healthcare, INC. | $14.43 | 2019 | |
| Circassia INC. | $11.85 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayesh Kanuga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.